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Abstract
Oxidation of low-density lipoprotein (LDL) generates
proinflammatory and prothrombotic mediators that may
play a crucial role in cardiovascular and inflammatory
diseases. In order to study platelet-activating compo-
nents of oxidized LDL 1-stearoyl-2-arachidonoyl-sn-glyc-
ero-3-phosphocholine, a representative of the major
phospholipid species in LDL, the 1-acyl-phosphatidyl-
cholines (PC), was oxidized by CuCl2 and H2O2. After sep-
aration by high-performance liquid chromatography,
three compounds were detected which induced platelet
shape change at low micromolar concentrations. Platelet
activation by these compounds was distinct from the
pathways stimulated by platelet-activating factor, lyso-
phosphatidic acid, lyso-PC and thromboxane A2, as evi-
denced by the use of specific receptor antagonists. Fur-
ther analyses of the oxidized phospholipids by electro-
spray ionization mass spectrometry structurally iden-
tified them as 1-stearoyl-2-azelaoyl-sn-glycero-3-phos-
phocholine (m/z 694; SAzPC), 1-stearoyl-2-glutaroyl-sn-
glycero-3-phosphocholine (m/z 638; SGPC), and 1-stea-
royl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocholine (m/z
622; SOVPC). These observations demonstrate that nov-
el 1-acyl-PC which had previously been found to stimu-
late interaction of monocytes with endothelial cells also
induce platelet activation, a central step in acute throm-
bogenic and atherogenic processes.
Copyright © 2005 S. Karger AG, Basel
Introduction
Growing evidence indicates that oxidation of low-den-
sity lipoproteins (LDL) plays an important role in athero-
genesis by stimulating proinflammatory processes in the
cells of the vascular wall [1]. In addition, oxidized LDL
also induces platelet activation, as reflected by platelet
shape change [2], increases in free cytosolic calcium levels
[3] and platelet aggregation [2, 4]. Activation of platelets
by oxidized LDL is of pathophysiological significance.
Firstly, upon rupture of soft lipid-rich plaques, oxidized
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LDL particles are exposed to circulating platelets, contrib-
uting to the formation of intravascular thrombi responsi-
ble for acute ischemic syndromes. Indeed, experimental
evidence indicates that the lipid-rich atheromatous core
and not the exposed collagen is thrombogenic [5]. Sec-
ondly, oxidatively modified LDL is present in the circula-
tion [6], and its plasma levels are elevated in patients with
coronary artery disease [7]. Platelet activation by circulat-
ing oxidized LDL might be one reason for the platelet
hyperreactivity often observed in these patients [8].
In vitro, oxidation of LDL results in the modification
of phospholipids, mainly of phosphatidylcholine (PC), the
major phospholipid in LDL, and oxycholesterol [9]. Pri-
marily, polyunsatured fatty acids in the sn-2 position of
the phospholipid are oxidized to hydroperoxides and sub-
sequently undergo fragmentation to aldehydes, which can
further modify amino groups in proteins and phospholip-
ids. Interestingly, oxidation of LDL predominantly mod-
ifies arachidonic acid and much less linoleic acid con-
tained in phospholipids [10]. Although several phospho-
lipids which stimulate monocytes and endothelial cells
have been identified in oxidized LDL [11–13], structural
characterization of platelet-activating molecules is lim-
ited. To this end, lysophosphatidic acid (LPA) has been
identified as the main platelet-activating lipid in mildly
oxidized LDL and atherosclerotic plaques [14]. Very
recently, a platelet-activating factor (PAF) analogue, 1-O-
hexadecyl-2-(5-oxovaleroyl)-sn-glycero-phosphocholine,
has been identified in human atheroma that induced
aggregation of rabbit platelets through activation of the
PAF receptor, whereas its 1-acyl-analogue, 1-palmitoyl-2-
(5-oxovaleroyl)-sn-glycero-phosphocholine, stimulated in
rabbits platelet shape change, which was independent
from the activation of the PAF receptor [15]. Further-
more, oxidation of PC has been found to result in the for-
mation of PAF-like compounds [16], which have been
partially characterized as sn-2-butanoyl and butenoyl
(C4)-PAF analogues [17]. Additional oxidized PC deriva-
tives have been characterized and found to stimulate
monocytes and endothelial cells. These substances are
formed from the predominant PC, ester-linked 1-acyl-2-
acyl-sn-glycero-phosphocholine, and the minor group of
PC, ether-linked 1-alkyl-2-acyl-sn-glycero-phosphocho-
line. Oxidation of the latter revealed formation of 1-
alkyl-2-azelaoyl-sn-glycero-phosphocholine that activated
the peroxisome proliferator-activated receptor-Á in mono-
cytes [18]. Furthermore, non-PAF-like phospholipid oxi-
dation products of 1-acyl-PC have been characterized
from minimally modified LDL and from human and rab-
bit atherosclerotic lesions as 1-palmitoyl-2-glutaroyl-sn-
glycero-phosphocholine and 1-palmitoyl-2-epoxyisopros-
tane-sn-glycero-phosphocholine [19, 20]. These sub-
stances stimulate endothelial binding of monocytes and
neutrophils [21] and the expression of tissue factor in
endothelial cells [22] through signaling pathways other
than the PAF receptor [23]. Furthermore, they may also
mitigate endotoxin shock in vivo [24].
This study was designed to assess whether oxidation
products of authentic 1-acyl-2-acyl-sn-glycero-phospho-
choline have platelet-activating effects and to structurally
identify these compounds. After oxidation of 1-stearoyl-
2-arachidonoyl-sn-glycero-phosphocholine (SAPC) with
CuCl2 and H2O2, three compounds were found to stimu-
late shape change in human platelets, which was indepen-
dent from the activation of the receptors for PAF, LPA or
thromboxane A2 (TxA2). Electrospray ionization-mass
spectrometry (ESI-MS) revealed that these compounds
were 1-stearoyl-2-azelaoyl-sn-glycero-3-phosphocholine
(m/z 694; SAzPC), 1-stearoyl-2-glutaroyl-sn-glycero-3-
phosphocholine (m/z 638; SGPC), and 1-stearoyl-2-
(5-oxovaleroyl)-sn-glycero-3-phosphocholine (m/z 622;
SOVPC).
Materials and Methods
Materials
Synthetic 1-stearoyl-2-[14C1]-arachidonoyl-sn-glycero-3-phospho-
choline (specific activity 54 mCi/mmol) was from Amersham
(Braunschweig, Germany). WEB 2086 was a kind gift from Dr. Dütt-
mann (Boehringer, Ingelheim, Germany) and N-palmitoyl tyrosine
phosphoric acid NPTyrPA was a kind gift from Dr. Bittman (Flush-
ing, N.Y., USA). SQ 29,548 and U46619 were obtained from Alexis
(Grünberg, Germany) and Calbiochem (Darmstadt, Germany), re-
spectively. All reagents used for phospholipid extraction, derivatiza-
tion and chromatography were of analytical grade and purchased
from Baker (Griesheim, Germany) or Merck (Darmstadt, Germany).
Synthetic 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine as
well as all other reagents were from Sigma (Deisenhofen, Germany).
Free Radical Oxidation and Extraction of SAPC
Free radical oxidation of SAPC was performed as described by
Harrison and Murphy [25], with slight modifications. In brief, 7.2 mg
of SAPC were placed in a glass tube and 0.5 ÌCi of 1-stearoyl-2-
[14C1]arachidonoyl-sn-glycero-3-phosphocholine was added as indi-
cated. After evaporation of the solvent under a stream of nitrogen,
SAPC was immediately resuspended in 50 Ìl of 98% ethanol fol-
lowed by addition of 4.8 ml of 50 mM Trizma buffer, pH 7.35. To
optimize the suspension, the solution was placed in an ultrasonic
water bath at full power for 2 min. Thereafter, SAPC was oxidized
with 600 mM H2O2 and 100 ÌM CuCl2 for 360 min at 37 °C. To
determine the time course of oxidative modification of SAPC, ali-
quots were taken at the time points indicated. Oxidation was termi-
nated by the addition of 1,000 units catalase for 10 min at 37°C.
Lipids were then extracted twice with 800 Ìl of water-saturated
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1-butanol and were dried under vacuum and stored at –80°C until
further analyses.
Reverse-Phase High-Performance Liquid Chromatography
RP-HPLC was performed with a C18 column (Nucleosil 100,
250 ! 4.6 mm, Macherey & Nagel, Düren, Germany) and a Supelco-
guard LC-18-DB precolumn (Supelco, Germany). Phospholipids
were eluted with a two-solvent gradient system starting with 80%
MeOH, 20% water containing 0.5 mM ammonium acetate for 25
min. Thereafter, the solvent changed linearly over 50 min to 100%
MeOH containing 0.5 mM ammonium acetate and continued with
this solvent for another 25 min. The flow rate was 1.5 or 2.0 ml/min.
Column temperature was held constant at 22°C with a Gynkotek
STH 585 column conditioner (Gynkotek, Germering, Germany).
UV absorbance was detected with a diode array detector (Gynkotek
UVD 320S) set at 205, 235, 242 and 270 nm. The eluent was col-
lected in 1-min fractions. Samples containing [14C]-labeled phospho-
lipids were counted in a liquid scintillation counter (Wallac 1410;
Pharmacia, Germany). Non-radioactive phospholipids were dried
under vacuum and stored at –80°C until further analyses.
Electrospray Ionization Mass Spectrometry 
ESI-MS and ESI-MS/MS spectra were measured using an Ap-
plied Biosystems API300 triple quadrupole mass spectrometer (Ap-
plied Biosystems, Weiterstadt, Germany) equipped with an in-house-
built nanospray source. For full scan spectra of the whole oxidation
mixture, the dried sample was diluted with 80% MeOH in 0.5 mM
ammonium acetate buffer and approximately 3 Ìl were transferred to
an in-house-pulled nanospray capillary tube and mounted in the
source. Usually, a small pressure of compressed air was applied to the
capillary tube to initiate the spray. The high voltage applied to the
capillary varied from 800 to 1,000 V in the positive mode and from
–600 to –800 V in the negative mode. The orifice voltage was opti-
mized for each experiment. Compressed nitrogen 5.0 (Linde, Pul-
lach, Germany) was used as curtain and as collision gas in MS/MS
experiments. The scan range was 500–1,000 m/z (2 s/scan) for the
ESI-MS spectra and 30 m/z units above the m/z value of the parent
ion (2 s/scan) for the ESI-MS/MS spectra.
Derivatization of Phospholipids
After purification and separation by RP-HPLC, 250 Ìg of the oxi-
dation product with m/z 622 was dried under argon, and 100 Ìl of
0.92 mM methoxyamine hydrochloride in phosphate-buffered saline
was added. The solution was mixed thoroughly and incubated for 45
min at room temperature. Thereafter, lipids were extracted with
CHCl3/MeOH and analyzed by ESI-MS or ESI-MS/MS. In parallel,
250 Ìg of each of the oxidation products with m/z 694 and 638 were
dried under argon, and 50 Ìl of 20% (w/w) N,N-diisopropylethyl-
amine in acetonitrile as well as 50 Ìl of 10% (w/w) pentafluorobenzyl
bromide in acetonitrile were added, respectively. The solutions were
mixed thoroughly and incubated for 45 min at room temperature.
Lipids were extracted with CHCl3/MeOH and analyzed by ESI-MS
or ESI-MS/MS.
Platelet Isolation and Determination of Platelet Shape Change 
Blood was taken from healthy volunteers and anticoagulated with
10% (v/v) citrate. After centrifugation at 180 g, platelet-rich plasma
was separated, acetylsalicylic acid (1 mM ) was added and platelets
were further isolated and washed as described [26]. Platelets were
resuspended at a concentration of 0.4 ! 106 platelets per milliliter in
buffer C (HEPES 20 mM, NaCl 138 mM, KCl 2.9 mM, MgCl2 1 mM,
NaH2PO4 0.36 mM, 0.6 ADPase units/ml apyrase, pH 7.4) and 0.16
! 106 platelets were transferred into aggregometer cuvettes and incu-
bated at 37°C while stirring at 1,100 rpm in an aggregometer. After 5
min, oxidation products that were resuspended at a concentration of
4 mM in ethanol/distilled water (50/50; v/v) or the agonists indicated
were added. Shape change was measured by the decrease in light
transmission [14]. Receptor antagonists were added 1 min prior to
the oxidation products or the specific platelet stimuli.
Determination of Free Cytosolic Calcium Concentrations in
Platelets 
Human platelets were prepared as described above without prior
treatment with acetylsalicylic acid. Determination of free cytosolic
calcium was performed as described previously [3]. In brief, platelets
(1 ! 109/ml) were loaded with the calcium-sensitive dye Fura-2/AM
(4 ÌM ) and incubated in the presence of bovine albumin (1 mg/ml)
for 1 h at 37°C in buffer C, washed with buffer C and resuspended in
buffer C at a concentration of 1 ! 109/ml in the presence of bovine
albumin (1 mg/ml). Before measurement, platelets were diluted to
0.2 ! 109/ml with buffer C and incubated for 5 min at 37°C before
CaCl2 (1 mM ) was added. Oxidation products or the agonists indi-
cated were added and fluorescence was measured using excitation
wavelengths of 340 and 380 nm and an emission wavelength of
510 nm. Free cytosolic calcium concentrations were calculated by the
modified Lambert-Beer formula as described previously [27].
Results
Separation of Oxidized SAPC by RP-HPLC
Oxidized SAPC was fully separated from unoxidized
SAPC by RP-HPLC. Determination of the time course of
oxidation revealed that SAPC was almost completely oxi-
dized to more polar compounds within 360 min (fig. 1A).
Three major compounds were formed (fig. 1B) which
eluted at about 9 min (compound 1), 16 min (compound
2) and 36 min (compound 3) after RP-HPLC. The UV
absorbance of compounds 1–3 was only weak at 205 nm
and virtually undetectable at 235, 242 or 270 nm, indicat-
ing that these compounds did not have the configuration
of conjugated dienes or trienes. Compound 3 was the
most prominent oxidation product, and was about twice
as much as compounds 1 and 2. To assess the biological
activity and the molecular structure of these compounds,
non-radioactive oxidation products of SAPC were col-
lected at the characteristic retention times and used for
further studies.
Platelet Shape Change and Free Cytosolic Calcium
after Exposure to Oxidized SAPC
Addition of either one of the three compounds at con-
centrations of 2.5 to 10 ÌM to washed human platelets
pretreated with acetylsalicylic acid resulted in the induc-
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Fig. 1. RP-HPLC chromatogram showing
the time course of SAPC oxidation. SAPC
(1.6 mg non-radioactive SAPC plus 0.5 ÌCi
[14C]-SAPC) was oxidized by CuCl2 and
H2O2 for the time periods indicated (A) or
for 360 min (B), separated by RP-HPLC as
detailed in the ‘Experimental Procedures’
and collected in 1-min intervals. Oxidation
products were detected by liquid scintilla-
tion. Note that the flow rate was 2.0 ml/min
(A) and 1.5 ml for better separation (B).
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tion of shape change (fig. 2A, B). The stimulatory activity
of each of the three compounds at a concentration of
10 ÌM was almost equal to the effect of 1 ÌM ADP.
Unoxidized SAPC (20 ÌM) did not stimulate platelet
shape change (fig. 2A). To assess the possible receptors
activated, receptor antagonists for phospholipid media-
tors and eicosanoids known to activate platelets were
used. Inhibition of the PAF receptor by WEB 2086
(1 ÌM) [28], the LPA receptor by N-palmitoyl tyrosine-
phosphoric acid (NPTyrPA, 1.2 ÌM) [29] or the TxA2
receptor by SQ 29,548 (2.5 ÌM) [30] did not affect shape
change induced by compound 1 (fig. 2B) or any one of the
other two compounds (data not shown). In contrast, shape
change was inhibited by WEB 2086, SQ 29,548 and
NPTyrPA in response to stimulation with the receptor
agonists PAF, U46619 and LPA, respectively (fig. 2C).
These observations indicated that the oxidation products
activate platelets by receptors distinct from PAF, LPA
and TxA2.
In contrast to stimulation with PAF, none of the three
compounds increased free cytosolic calcium concentra-
tions ([Ca2+]i), determined by fluorometric measurements
of Fura-2-loaded platelets. As shown in figure 3, stimula-
tion with compound 1 (10 ÌM) did not affect [Ca2+]i,
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Fig. 2. Induction of platelet shape change by
the three major oxidation products of SAPC.
A Suspensions of washed human platelets
were stimulated by increasing concentra-
tions of compound 1 (upper part) or with
compounds 2 or 3 (each 10 ÌM ), ADP
(1 ÌM ) or unoxidized SAPC (20 ÌM; lower
part). B Suspensions of washed human
platelets were preincubated with WEB 2086
(1.0 ÌM ) or SQ 29,548 (2.5 ÌM ) for 1 min or
NPTyrPA (1.2 ÌM ) for 15 min and stimulat-
ed with compound 1 (10 ÌM ). C Suspen-
sions of washed human platelets were prein-
cubated with WEB 2086 (1.0 ÌM ), SQ
29,548 (2.5 ÌM ) and NPTyrPA (1.2 ÌM )
and stimulated with PAF (1.0 ÌM ), U46619
(50 nM ) and LPA (50 nM ), respectively.
Shape change was determined in an aggre-
gometer. The decrease in light transmission
together with the disappearance of rapid os-
cillations is indicative of shape change. Trac-
ings shown are representative of at least 5
separate experiments for each agonist.
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whereas subsequent addition of PAF (2.5 ÌM ) to the same
platelet preparation induced a characteristic rise in
[Ca2+]i, indicating that signalling of compound 1 differed
from PAF. The same observations were made with the
other two compounds (data not shown).
Purity Control of Purchased SAPC
To exclude contamination of the purchased SAPC, a
positive ion mode ESI-MS analysis was performed. There
was only one major peak detectable at m/z 811 with repre-
sents SAPC (fig. 4). The small peak at m/z 832.9 repre-
sents a sodium adduct during ESI-MS analysis.
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Structural Analysis of Compound 1
Nano-ESI-MS analysis in the positive ion mode of RP-
HPLC-purified compound 1 revealed a major peak at m/z
694 (fig. 5A). The compound at m/z 694 would be com-
patible with an oxidatively modified form of SAPC pos-
sessing a 9-carbon moiety with a terminal carboxylic acid,
azelaic acid, at the sn-2 position and unmodified moieties
at the sn-1 (stearic acid) and sn-3 (phosphocholine) posi-
tions. This molecule, 1-stearoyl-2-azelaoyl-sn-glycero-3-
phosphocholine, would produce a (M+H)+ ion at m/z 694.
To prove this assumption, compound 1 was derivatized
with pentafluorobenzyl bromide which is used to deriva-
tize carboxylic acids and would add a pentafluorobenzyl
group (180 Da) to the 9-carbon group at the sn-2 position.
After treatment, ESI-MS analyses showed a reduced
amount of the compound at m/z 694, and a major com-
pound at m/z 874 becomes detectable, which was not
present before (fig. 5B).
The structural identity of compound 1 was further con-
firmed by ESI-MS/MS analyses. In the positive ion mode,
the product ion scan for (M+H)+ at m/z 694 showed the
ion pattern m/z 184, 104 and 86, which is typical for lip-
ids containing phosphocholine (data not shown) [36].
Fig. 3. Effects of the three major oxidation products on the release of
intracellular calcium in platelets. A suspension of washed human
platelets was loaded with Fura-2/AM and stimulated with compound
1 (10 ÌM ) or with PAF (2.5 ÌM ). Fluorescence was measured using
excitation wavelengths of 340 and 380 nm and an emission wave-
length of 510 nm. Tracings shown are representative of 3 separate
experiments. Tracings for compounds 2 or 3 did not differ from the
tracing shown for compound 1.
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Fig. 4. ESI-MS control of SAPC purity. To
exclude contamination of the non-oxidized
SAPC+ ion, ESI-MS analysis was performed.
There were no contaminations with other
substances, while there was only one rele-
vant peak at m/z 811 detectable. The small
peak at 832.9 m/z represents a sodium ad-
duct during ESI-MS measurement. The mo-
lecular structure of SAPC is also presented.
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ESI-MS analysis in the negative ion mode revealed the
major peak as expected for (M–H)– at m/z 692. MS/MS
studies on this parent ion produced signals at m/z 633,
508, 283, 201 and 169 (fig. 5C) consistent with the parent
ion after a loss of trimethylamine (633), the unmodified
stearoyl moiety (283) and the claimed azelaoyl moiety
(169). Peaks at m/z 508 and 201 are the consequence of
the well-known phenomenon of a methyl shift from the
choline moiety to terminal carboxylic groups in the sn-2
position under fragmentation conditions [31] (see inset of
fig. 5C for structural details). From these observations, we
conclude that compound 1 is 1-stearoyl-2-azelaoyl-sn-
glycero-3-phosphocholine (SAzPC).
Structural Analysis of Compound 2
Nano-ESI-MS analyses in the positive ion mode of RP-
HPLC-purified compound 2 revealed a major peak at m/z
638 (fig. 6). This would be compatible with an oxidatively
more shortened version of compound 1, possessing a glu-
taryl moiety in the sn-2 position instead of the azelaoyl.
This molecule, 1-stearoyl-2-glutaroyl-sn-glycero-3-phos-
phocholine, produced a (M+H)+ ion at m/z 638. To prove
the structural identity, the same set of experiments was
performed on compound 2 as on compound 1 (data not
shown). From these observations, we conclude that com-
pound 2 is 1-stearoyl-2-glutaroyl-sn-glycero-3-phospho-
choline (SGPC).
Structural Analysis of Compound 3
Nano-ESI-MS analyses in the positive ion mode of RP-
HPLC-purified compound 3 revealed a major peak at m/z
622 (fig. 7), which suggests the molecule to be the alde-
hyde analogue of compound 2, thus having 5-oxovaleric
acid esterified at the sn-2 position. A specific derivatiza-
tion method was chosen to prove the presence of a termi-
nal aldehyde group. Positive ESI-MS/MS experiments
showed further evidence for its chemical structure (data
not shown).
From these observations, we conclude that compound
3 is 1-stearoyl-2-(5-oxovaleroyl)-sn-glycero-3-phospho-
choline (SOVPC).
Fig. 5. Identification of compound 1 (m/z 694) as 1-stearoyl-2-aze-
laoyl-sn-glycero-3-phosphocholine by ESI-MS and ESI-MS/MS. Oxi-
dized SAPC (1.6 mg) was separated by RP-HPLC. The fraction con-
taining compound 1 was dried and dissolved in 80% MeOH in
0.5 mM ammonium acetate. Analysis by positive ion ESI-MS fol-
lowed either directly (A) or after treatment with pentafluorobenzyl
bromide (B). Negative ion ESI-MS/MS was performed on the parent
ion at m/z 692 without prior derivatization (C). Proposed molecular
structures and fragmentation patterns are also presented.
(For figure 5C see page 128.)
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Fig. 6. Identification of compound 2 (m/z 638) as 1-stearoyl-2-glutaryl-sn-glycero-3-phosphocholine by ESI-MS. Oxi-
dized SAPC (1.6 mg) was separated by RP-HPLC. The fraction containing compound 2 was dried and dissolved in
80% MeOH in 0.5 mM ammonium acetate. Analysis by positive ion ESI-MS followed directly. The molecular struc-
ture of compound 2 is also presented.
Fig. 7. Identification of compound 3 (m/z 622) as 1-stearoyl-2-(5-oxovaleryl)-sn-glycero-3-phosphocholine by ESI-
MS. Oxidized SAPC (1.6 mg) was separated by RP-HPLC. The fraction containing compound 3 was dried and
dissolved in 80% MeOH in 0.5 mM ammonium acetate. Analysis by positive ion ESI-MS followed directly. The
molecular structure of compound 3 is also presented.
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Discussion
Each of the three major oxidation products of 1-acyl-
PC, SAzPC, SGPC and SOVPC, induced shape change in
human platelets, which is the initial step of platelet activa-
tion. The potency of the three compounds was similar.
Platelet activation induced by SAzPC, SGPC and SOVPC
was not mediated by stimulation of the PAF receptor,
LPA receptor or TxA2 receptor. Unlike PAF, these com-
pounds did not increase [Ca2+]i in platelets, further dem-
onstrating that they activate platelets by a pathway dis-
tinct from PAF. These observations indicate that oxida-
tion of the major phospholipid of LDL, 1-acyl-2-acyl-sn-
glycero-phosphocholine, leads to the formation of distinct
phospholipids fragmented at the sn-2 position that acti-
vate platelets through as yet unknown mechanisms.
Generation of SOVPC and SGPC by oxidation of
authentic 1-acyl-PC has been reported previously [19, 23],
and it has been found that they stimulate monocyte endo-
thelial cell interaction. This report now demonstrates that
these products derived from oxidation of 1-acyl-2-acyl-sn-
glycero-phosphocholine do also activate human platelets.
Chemically synthesized PC with short-chain fatty-acid
derivatives at the sn-2 position has earlier been reported
to stimulate serotonin secretion from rabbit platelets and
aggregation of human platelets [33]. The most active com-
pounds were PAF-like 1-O-hexadecyl-2-acyl-sn-glycero-
phosphocholine derivatives. Among the 1-acyl-deriva-
tives, 1-palmitoyl-2-glutaroyl-PC, which is structurally
similar to SGPC identified in our study, stimulated sero-
tonin secretion from rabbit platelets that was sensitive to
PAF receptor antagonists. However, this substance did
not stimulate aggregation of human platelets [33]. Very
recently, the PAF-like compound 1-O-hexadecyl-2-(5-
oxovaleroyl)-sn-glycero-phosphocholine has been identi-
fied in human atheroma and found to stimulate aggrega-
tion of rabbit platelets through activation of the PAF
receptor [15]. In contrast, the corresponding 1-acyl com-
pound, 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-phos-
phocholine (POVPC), induced only shape change that
was not suppressed by PAF receptor antagonists [15].
POVPC is structurally almost identical to SOVPC identi-
fied in our study, which induced shape change in human
platelets independent from the activation of the PAF
receptor. Formation of SAzPC has been detected after
oxidation of 1-alkyl-PC [18, 34]; however, based on our
knowledge, the stimulating effects of SazPC, or a structur-
ally similar substance, on platelet activation have not yet
been reported.
Platelet activation by PAF or structurally similar phos-
pholipids through the PAF receptor is an important event
in inflammatory and thrombotic conditions. The PAF
receptor is highly specific for phospholipids with the fol-
lowing structural characteristics: an sn-1 ether bond, an
sn-2 acetyl residue and a choline head group [35, 36]. This
preference excludes activation of the PAF receptor by sev-
eral sn-1 acyl phosphocholines as compared to their sn-1
alkyl analogues [15, 17]. Similarly, we found that the sn-1
acyl PC derivatives, SOVPC, SOGPC and SazPC, did not
stimulate platelet shape change by activation of the PAF
receptor. Furthermore, these compounds neither inter-
acted with the lipid phosphatidate receptors Edg-2 or Edg-
4 for LPA [37] nor with the SQ 29,548-sensitive receptors
for TxA2, which can also be activated by isoprostanes
[38]. In addition, it is very unlikely that the oxidized phos-
pholipids induced platelet activation by membrane per-
turbation or toxic effects since they did not induce
changes in free cytosolic calcium concentrations [39] and
since stimulation with PAF increased [Ca2+]i even after
addition of the oxidized phospholipids.
The putative proatherogenic and prothrombotic role of
glutaroyl-PC and 5-oxovaleroyl-PC is supported by their
detection in oxidized LDL and in human and animal ath-
erosclerotic lesions. The presence of 1-acyl(C16 or C18)-2-
oxovaleroyl-PC has been reported in extensively oxidized
LDL and HDL [40], in minimally or mildly oxidized LDL
[19] and in human as well as in rabbit atheroma [15, 19].
In addition, 1-acyl(C16 or C18)-2-glutaroyl-PC has been
identified in mildly oxidized LDL and rabbit atheroscle-
rotic lesions [19]. Therefore, the platelet-activating oxida-
tive derivatives of 1-acyl-PC identified in our study, i.e.
SOVPC and SGPC, are generated and present in vivo.
Platelet activation induced by the compounds identified
in these analyses started at concentrations of about
2.5 ÌM. In previous studies, fragmented diacyl-PC with
short oxidized sn-2 residues were found in blood plasma
of young healthy adults in concentrations of about 2.5 ÌM
and increased significantly in elderly patients with coro-
nary heart disease to concentrations of about 4.0 ÌM.
Measurements during acute smoking revealed concentra-
tions of up to 7 ÌM in healthy volunteers [41]. Further-
more, regarding acute plaque rupture, there will be much
higher local concentrations of oxidized phospholipids fol-
lowing the release of plaque lipids. Therefore, the phos-
pholipids identified in this study might play a relevant
role in platelet activation in vivo.
In summary, the major 1-acyl-PC oxidation products
SAzPC, SGPC and SOVPC, were found to induce platelet
shape change through a pathway distinct to the activation
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of the receptors for PAF, LPA and TxA2. These com-
pounds are likely to participate in platelet activation
induced by oxidized LDL, which is present in the circula-
tion of patients with cardiovascular disease or is exposed
upon rupture or erosion of atherosclerotic plaques. In con-
cert with their stimulatory effects on monocytes and
endothelial cells, these novel phospholipid oxidation
products may not only be important mediators in athero-
genesis and inflammation, but also in thrombotic pro-
cesses.
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